Strumento inattivo

Azioni Ariad Pharmaceuticals, Inc.

Azioni

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

Ariad Pharmaceuticals : Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency	06/02/17
Ariad Pharmaceuticals : Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion	03/02/17
Ariad Pharmaceuticals : Takeda to Acquire ARIAD Pharmaceuticals, Inc.	03/02/17
Ariad Pharmaceuticals : Acquisition May Not Be in the Best Interests of ARIA Shareholders	18/01/17
Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	13/01/17

Dirigenti	Titolo	Età	Da
Teresa Bitetti PSD	President	-	-
Tetsu Inada BRD	Director/Board Member	-	-
Jason E. Baranski SEC	Corporate Secretary	-	-

Amministratori	Titolo	Età	Da
Teresa Bitetti PSD	President	-	-
Tetsu Inada BRD	Director/Board Member	-	-

Settore

	Variaz. 1 gen.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31%	103 Mrd
REGENERON PHARMACEUTICALS, INC.	+0,56%	95,28 Mrd
ARGENX SE	+1,69%	22,15 Mrd
BIONTECH SE	-17,37%	21,02 Mrd
GENMAB A/S	-9,30%	18,15 Mrd
WUXI APPTEC CO., LTD.	-41,01%	16,74 Mrd
BEIGENE, LTD.	-14,85%	16,05 Mrd
NEUROCRINE BIOSCIENCES, INC.	+3,21%	13,68 Mrd
SAREPTA THERAPEUTICS, INC.	+33,54%	12,17 Mrd